912762-53-9 Usage
Uses
Used in Chemical Synthesis:
[2-HYDROXYIMINO-2-(3-METHOXY-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a reagent in the chemical synthesis industry for the creation of more complex molecules. Its unique structure allows it to serve as a building block or intermediate in the synthesis of various compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [2-HYDROXYIMINO-2-(3-METHOXY-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a research compound to explore its potential as a therapeutic agent. Its specific properties and interactions with biological systems would need further investigation to determine its suitability for drug development.
Used in Material Science:
[2-HYDROXYIMINO-2-(3-METHOXY-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER may also find applications in material science, where its unique chemical structure could be utilized to develop new materials with specific properties, such as improved stability or reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 912762-53-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,7,6 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 912762-53:
(8*9)+(7*1)+(6*2)+(5*7)+(4*6)+(3*2)+(2*5)+(1*3)=169
169 % 10 = 9
So 912762-53-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H20N2O4/c1-14(2,3)20-13(17)15-9-12(16-18)10-6-5-7-11(8-10)19-4/h5-8,18H,9H2,1-4H3,(H,15,17)/b16-12+
912762-53-9Relevant academic research and scientific papers
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors
Dinges, Jurgen,Harris, Christopher M.,Wallace, Grier A.,Argiriadi, Maria A.,Queeney, Kara L.,Perron, Denise C.,Dominguez, Eric,Kebede, Tegest,Desino, Kelly E.,Patel, Hetal,Vasudevan, Anil
, p. 2297 - 2302 (2016/04/20)
Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.
